Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
CG Oncology, Inc. - Common stock
(NQ:
CGON
)
39.06
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
39.06
Bid (Size)
37.05 (10)
Ask (Size)
40.50 (4)
Prev. Close
39.06
Today's Range
39.06 - 39.06
52wk Range
25.77 - 50.23
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
November 06, 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 24, 2024
Via
Benzinga
Performance
YTD
-1.49%
-1.49%
1 Month
+12.18%
+12.18%
3 Month
+17.51%
+17.51%
6 Month
+30.11%
+30.11%
1 Year
-1.49%
-1.49%
More News
Read More
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 30, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024
August 08, 2024
Via
InvestorPlace
A Closer Look at 9 Analyst Recommendations For CG Oncology
June 28, 2024
Via
Benzinga
Decoding 10 Analyst Evaluations For CG Oncology
May 14, 2024
Via
Benzinga
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
June 03, 2024
Via
Benzinga
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
May 03, 2024
Via
Benzinga
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
May 03, 2024
Via
Benzinga
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
IPO Stocks: Will Reddit Unplug The Bulging U.S. IPO Pipeline?
March 28, 2024
Via
Investor's Business Daily
Topics
Initial Public Offering
Exposures
Securities Market
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
March 28, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
February 27, 2024
From
CG Oncology Inc.
Via
GlobeNewswire
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
February 25, 2024
Via
The Motley Fool
Topics
Initial Public Offering
Exposures
Securities Market
3 attractive stocks that insiders are buying
February 12, 2024
Via
MarketBeat
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
February 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.